SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zim Laboratories files regulatory dossier for approval of Rizatriptan orally dissolving film

08 Jul 2020 Evaluate

Zim Laboratories has filed the regulatory dossier for approval of Rizatriptan orally dissolving film in Europe. Rizatriptan orally dissolving film is a product developed using its Thinoral technology which yields instantly wettable, rapidly dissolving, and stable films.

The product is used in the treatment of migraine which is invariably associated with symptoms like nausea and vomiting. The submission of the Rizatriptan orally dissolving film MAA represents a critical milestone for ZIM and for European patients suffering from Migraine.

Zim Laboratories has established itself as one of the preferred healthcare solution providers in the field of New Drug Delivery Systems (NDDS).

Zim Laboratories Share Price

79.72 3.72 (4.89%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×